ALKSAlkermes plc

Alkermes plc (Nasdaq: ALKS) today announced detailed positive results from the Vibrance-2 phase 2 dose-ranging study evaluating alixorexton in patients with narcolepsy type 2 (NT2). Once-daily alixorexton met the studys dual primary endpoints, demonstrating statistically significant and clinically...

Alkermes wins orphan drug designations in the United States and Europe for alixorexton for treating idiopathic hypersomnia and narcolepsy, respectively.

Alkermes plc (Nasdaq: ALKS) today announced that alixorexton, a novel, investigational, oral, selective orexin 2 receptor (OX2R) agonist in development for the treatment of narcolepsy type 1 (NT1), narcolepsy type 2 (NT2) and idiopathic hypersomnia (IH), was recently granted orphan drug...

Revolution Medicines (RVMD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Alkermes (ALKS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Alkermes plc (Nasdaq: ALKS) today announced plans to present new data from its industry-leading portfolio of sleep medicine research at SLEEP 2026, the 40th annual meeting of the Associated Professional Sleep Societies (APSS), taking place June 14-17, 2026 in Baltimore, MD. The company will present...

Alkermes plc (Nasdaq: ALKS) announced today that management will participate in a fireside chat at the Goldman Sachs 47th Annual Global Healthcare Conference on Wednesday, June 10, 2026 at 10:00 a.m. ET (3:00 p.m. BST). The live webcast may be accessed under the Investors tab on www.alkermes.com...

Alkermes plc (Nasdaq: ALKS) today announced plans to present clinical and real-world data related to the companys psychiatry and orexin portfolios at the American Society of Clinical Psychopharmacology Annual Meeting, taking place May 26-29, 2026 in Miami. The poster presentations include data...

Alkermes plc (Nasdaq: ALKS) today announced the presentation of accepted research at key scientific conferences this spring related to its psychiatry productsLYBALVI (olanzapine and samidorphan) and ARISTADA (aripiprazole lauroxil)and its ongoing involvement in sleep medicine. The data presented...